Summary of Product Characteristics
last updated on the eMC:
27/01/2012
|
SPC
|
Arythmol 150mg and 300mg Tablets
|
Go to top of the pageGo to top of the page | Each tablet contains 150 mg or 300 mg propafenone HCl. | |
Go to top of the pageGo to top of the pageGo to top of the page | Arythmol is indicated for the prophylaxis and treatment of ventricular arrhythmias.Arythmol is also indicated for the prophylaxis and treatment of paroxysmal supraventricular tachyarrhythmias which include paroxysmal atrial flutter/fibrillation and paroxysmal re-entrant tachycardias involving the AV node or accessory bypass tracts, when standard therapy has failed or is contra-indicated. | |
Go to top of the page | It is recommended that Arythmol therapy should be initiated under hospital conditions, by a physician experienced in the treatment of arrhythmias. The individual maintenance dose should be determined under cardiological surveillance including ECG monitoring and blood pressure control. If the QRS interval is prolonged by more than 20%, the dose should be reduced or discontinued until the ECG returns to normal limits. Adults: Initially, 150 mg three times daily increasing at a minimum of three-day intervals to 300 mg twice daily and if necessary, to a maximum of 300 mg three times daily.Dose increases should not be attempted until the patient has been receiving treatment for three to four days. The tablets should be swallowed whole and taken with a drink after food. A reduction in the total daily dose is recommended for patients below 70 kg bodyweight. Elderly: No overall differences in safety or effectiveness were observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out, therefore, these patients should be carefully monitored. Treatment should be initiated gradually and with particular caution in small incremental doses.The same applies to maintenance therapy. Any dose increases that may be required should not be undertaken until after five to eight days of therapy. Children: A suitable dosage form of Arythmol for children is not available.Hepatic/Renal Impairment: In patients whose liver and/or kidney function is impaired, there may be drug accumulation after standard therapeutic doses. Nonetheless, patients with these conditions can still be titrated on propafenone hydrochloride under ECG and plasma level monitoring. | |
Go to top of the page | Known hypersensitivity to propafenone or to any of the other ingredients.Arythmol is contraindicated in patients with known Brugada Syndrome.Arythmol is contraindicated in patients with significant structural heart disease such as patients with an incident of myocardial infarction within the last 3 months,uncontrolled congestive heart failure where left ventricular output is less than 35%, cardiogenic shock (unless arrhythmia-induced), severe symptomatic bradycardia, manifest electrolyte imbalance (e.g., potassium metabolism disorders), severe obstructive pulmonary disease or severe hypotension. Arythmol may worsen myasthenia gravis. Unless patients are adequately paced (see section 4.4, Special Warnings and Precautions for Use), Arythmol should not be used in the presence of sinus node dysfunction, atrial conduction defects, second degree or greater AV block, bundle branch block or distal block.Due to the potential for increased plasma concentrations, co-administration of ritonavir and propafenone hydrochloride is contraindicated. | |
Go to top of the page | The weak negative inotropic effect of Arythmol may assume importance in patients predisposed to cardiac failure. In common with other anti-arrhythmic drugs, Arythmol has been shown to alter sensitivity and pacing threshold. In patients with pacemakers, appropriate adjustments may be required. There is potential for conversion of paroxysmal atrial fibrillation to atrial flutter with accompanying 2:1 conduction block or 1:1 conduction (see section 4.8).Because of the beta-blocking effect, care should be exercised in the treatment of patients with obstructive airways disease e.g., asthma. As with some other class Ic anti-arrhythmic agents, patients with significant structural heart disease may be predisposed to serious adverse events. Therefore propafenone is contraindicated in these patients (see section 4.3).A Brugada syndrome may be unmasked or Brugada like electrocardiogram (ECG) changes may be provoked after exposure to propafenone in previously asymptomatic carriers of the syndrome. After initiating therapy with propafenone, an ECG should be performed to rule out changes suggestive of Brugada syndrome.It is essential that each patient given Arythmol be evaluated electrocardiographically and clinically prior to and during therapy to determine whether the response to Arythmol supports continued treatment. | |
Go to top of the page | Potential increase in adverse reactions may occur when propafenone is taken in conjunction with local anaesthetics (e.g., pacemaker implantation, surgery or dental work) and other medicinal products which have an inhibitory effect on the heart rate and/or myocardial contractility (e.g., beta blockers, tricyclic antidepressants).No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen following their concomitant use in patients. However, concomitant use of propafenone hydrochloride and intravenous lidocaine have been reported to increase the risks of central nervous system side effects of lidocaine.Increased plasma levels and/or blood levels of propranolol, metoprolol, desipramine, ciclosporin, theophylline and digoxin have been reported during propafenone therapy. Doses of these medicinal products should be reduced, as appropriate, if signs of overdose are observed.Elevated levels of plasma propafenone may occur when propafenone is used concomitantly with SSRIs, such as fluoxetine and paroxetine. Concomitant administration of propafenone and fluoxetine in extensive metabolisers increases the S-propafenone Cmax and AUC by 39 and 50% and the R-propafenone Cmax and AUC by 71 and 50%. Lower doses of propafenone may therefore be sufficient to achieve the desired therapeutic response.Close monitoring of the clotting status in patients receiving concomitant oral anticoagulants (e.g., phenprocoumon, warfarin) is recommended as propafenone may enhance the plasma levels of these medicinal products resulting in an increased prothrombin time. Doses of these medicinal products should be adjusted if necessary.Coadministration of propafenone hydrochloride with drugs metabolised by CYP2D6 (such as venlafaxine) might lead to increased levels of these drugs.Medicinal products that inhibit CYP2D6, CYP1A2 and CYP 3A4 e.g., ketoconazole, cimetidine, quinidine, erythromycin and grapefruit juice might lead to increased levels of propafenone. When propafenone is administered with inhibitors of these enzymes, the patients should be closely monitored and the dose adjusted accordingly.Combination therapy of amiodarone and propafenone hydrochloride can affect conduction and repolarisation and lead to abnormalities that have the potential to be proarrhythmic. Dose adjustments of both compounds based on therapeutic response may be required.Concomitant use of propafenone and phenobarbital and/or rifampicin (CYP3A4 inducers) may reduce the antiarrythmic efficacy of propafenone as a result of a reduction in propafenone plasma levels. Hence, response to propafenone hydrochloride therapy should be monitored during concomitant chronic phenobarbital and/or rifampicin treatment. | |
Go to top of the page | Pregnancy: There are no adequate and well-controlled studies in pregnant women. Propafenone should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.Propafenone is known to pass the placental barrier in humans. The concentration of propafenone in the umbilical cord has been reported to be about 30% of that in the maternal blood.Lactation: Excretion of propafenone in human breast milk has not been studied. Limited data suggests that propafenone may be excreted in human breast milk. Propafenone should be used with caution in nursing mothers. | |
Go to top of the page | Blurred vision, dizziness, fatigue and postural hypotension may affect the patient's speed of reaction and impair the individual's ability to operate machinery or motor vehicles. | |
Go to top of the page | a. Summary of the safety profile The most frequent and very common adverse reactions related to propafenone therapy are dizziness, cardiac conduction disorders and palpitations. b. Tabulated summary of adverse reactions The following table displays adverse reactions reported in clinical trials and from post-marketing experience with propafenone. The reactions considered at least possibly related to propafenone are displayed by system organ class and frequency using the following convention: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed. The frequencies are based on clinical trial data from propafenone SR.| System Organ Class | Very common 1/10 | Common 1/100 to < 1/10 | Uncommon 1/1,000 to < 1/100 | Not Known(cannot be estimated from the available data) | | Blood and lymphatic system disorders
| | | Thrombocytopenia
| Agranulocytosis
Leukopenia
Granulocytopenia
| | Immune system disorders
| | | | Hypersensitivity1 | | Metabolism and nutrition disorders
| | | Decreased appetite
| | | Psychiatric disorders | | Anxiety
Sleep disorders
| Nightmare
| Confusional state
| | Nervous system disorders
| Dizziness2 | Headache
Dysgeusia
| Syncope
Ataxia
Paraesthesia
| Convulsion
Extrapyramidal symptoms
Restlessness
| | Eye disorders
| | Vision blurred
| | | | Ear and labyrinth disorders
| | | Vertigo
| | | Cardiac disorders
| Cardiac conduction disorders3Palpitations
| Sinus bradycardia
Bradycardia
Tachycardia
Atrial flutter
| Ventricular tachycardia
Arrythmia4 | Ventricular fibrillation
Cardiac failure5Heart rate reduced
| | Vascular disorders
| | | Hypotension
| Orthostatic hypotension
| | Respiratory, thoracic and mediastinal disorders
| | Dyspnoea
| | | | Gastrointestinal disorders
| | Abdominal pain
Vomiting
Nausea
Diarrhoea
Constipation
Dry mouth
| Abdominal distension
Flatulence
| Retching
Gastrointestinal disturbance
| | Hepatobiliary disorders
| | Hepatic function abnormal6 | | Hepatocellular injury
Cholestasis
Hepatitis
Jaundice
| | Skin and subcutaneous tissue disorders
| | | Urticaria
Pruritus
Rash
Erythema
| | | Musculoskeletal and connective tissue disorders
| | | | Lupus-like syndrome
| | Reproductive system and breast disorders
| | | Erectile dysfunction
| Sperm count decreased7 | | General disorders and administration site conditions
| | Chest pain
Asthenia
Fatigue
Pyrexia
| | | 1 May be manifested by cholestasis, blood dyscrasias and rash2 Excluding vertigo3 Including sinoatrial block, atrioventricular block and intraventricular block4 Propafenone may be associated with proarrhythmic effects which manifest as an increase in heart rate (tachycardia) or ventricular fibrillation. Some of these arrhythmias can be life- threatening and may require resuscitation to prevent a potentially fatal outcome5 An aggravation of preexisting cardiac insufficiency may occur6 This term covers abnormal liver function tests, such as aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased and blood alkaline phosphatase increased7 Decreased sperm count is reversible upon discontinuation of propafenone | |
Go to top of the page | Symptoms of overdosing: Myocardial symptoms: The effects of propafenone overdose in the myocardium manifest as impulse generation and conduction disorders such as PQ prolongation, QRS widening, suppression of sinus node automaticity, AV block, ventricular tachycardia and ventricular fibrillation. Reduction of contractility (negative inotropic effect) can cause hypotension which, in severe cases, can lead to cardiovascular shock.Non-cardiac symptoms: Headache, dizziness, blurred vision, paraesthesia, tremor, nausea, constipation and dry mouth may occur frequently. In extremely rare cases, convulsions have been reported on overdose. Death has also been reported.In severe cases of poisoning, clonic-tonic convulsions, paraesthesia, somnolence, coma and respiratory arrest may occur.Treatment: In addition to general emergency measures, the patient's vital parameters should be monitored in an intensive care setting, and rectified, as appropriate.Defibrillation as well as infusion of dopamine and isoproterenol have been effective in controlling rhythm and blood pressure. Convulsions have been alleviated with intravenous diazepam. General supportive measures such as mechanical respiratory assistance and external cardiac massage may be necessary.Attempts to achieve elimination via haemoperfusion are of limited efficacy.Owing to high protein binding (> 95%) and the large volume of distribution, haemodialysis is ineffective. | |
Go to top of the pageGo to top of the page | Propafenone is a class IC anti-arrhythmic agent.It has a stabilising action on myocardial membranes, reduces the fast inward current carried by sodium ions with a reduction in depolarisation rate and prolongs the impulse conduction time in the atrium, AV node and primarily, in the His-Purkinje system.Impulse conduction through accessory pathways, as in WPW syndrome, is either inhibited, by prolongation of the refractory period or blockade of the conduction pathway, both in anterograde but mostly retrograde direction.At the same time, spontaneous excitability is reduced by an increase of the myocardial stimulus threshold while electrical excitability of the myocardium is decreased by an increase of the ventricular fibrillation threshold.Anti-arrhythmic effects: Slowing of upstroke velocity of the action potential, decrease of excitability, homogenisation of conduction rates, suppression of ectopic automaticity, lowered myocardial disposition to fibrillation.Propafenone has moderate beta-sympatholytic activity without clinical relevance. However, the possibility exists that high daily doses (900 - 1200 mg) may trigger a sympatholytic (anti-adrenergic) effect.In the ECG, propafenone causes a slight prolongation of P, PR and QRS intervals while the QTC interval remains unaffected as a rule.In digitalised patients with an ejection fraction of 35-50%, contractility of the left ventricle is slightly decreased. In patients with acute transmural infarction and heart failure, the intravenous administration of propafenone may markedly reduce the left ventricular ejection fraction but to an essentially lesser extent in patients in the acute stages of infarction without heart failure. In both cases, pulmonary arterial pressure is minimally raised. Peripheral arterial pressure does not show any significant changes. This demonstrates that propafenone does not exert an unfavourable effect on left ventricular function which would be of clinical relevance. A clinically-relevant reduction of left ventricular function is to be expected only in patients with pre-existing poor ventricular function.Untreated heart failure might then deteriorate possibly resulting in decompensation. | |
Go to top of the page | Following oral administration, propafenone is nearly completely absorbed from the gastrointestinal tract in a dose-dependent manner and distributed rapidly in the body. After a single dose of one tablet, bioavailability is about 50%. With repeated doses, plasma concentration and bioavailability rise disproportionately due to saturation of the first pass metabolism in the liver. Steady state is reached after 3 or 4 days, when bioavailability increases to about 100%. Therapeutic plasma levels are in the range of 150 ng/ml to 1500 ng/ml. In the therapeutic concentration range, more than 95% of propafenone is bound to plasma proteins. Comparing cumulative urinary excretion over 24 hours allowed for the calculation that 1.3% of intravenous (70 mg) and 0.65% of oral (600 mg) propafenone is excreted unchanged in the urine, i.e. propafenone is almost exclusively metabolised in the liver. Even in the presence of impaired renal function, reduced elimination of propafenone is not likely, which is confirmed by case reports and single kinetic studies in patients on chronic haemodialysis. Clinical chemistry values did not differ from those of patients with uncompromised kidneys. Terminal elimination half-life in patients is 5-7 hours (12 hours in single cases) following repeated doses. A close positive correlation between plasma level and AV conduction time was seen in the majority of both healthy volunteers and patients. After a plasma level of 500 ng/ml, the PR interval is statistically significantly prolonged as compared to baseline values which allows for dose titration and monitoring of the patients with the help of ECG readings. The frequency of ventricular extrasystoles decreases as plasma concentrations increase. Adequate anti-arrhythmic activity has, in single cases, been observed at plasma levels as low as <500 ng/ml. | |
Go to top of the pageGo to top of the pageGo to top of the page | Microcrystalline cellulose, maize starch, hypromellose, croscarmellose sodium, purified water, macrogol 6000, titanium dioxide, macrogol 400 and magnesium stearate. | |
Go to top of the pageGo to top of the pageGo to top of the pageGo to top of the page | Arythmol Tablets 150 mg: PVC/aluminium blister strips containing 90 tablets.Arythmol Tablets 300 mg: PVC/aluminium blister strips containing 60 tablets. | |
Go to top of the pageGo to top of the page | Abbott Laboratories Ltd.,Abbott House, Vanwall Business Park, Vanwall Road,Maidenhead, Berkshire,SL6 4XE,United Kingdom | |
Go to top of the page | | Arythmol 150 mg Tablets
| PL 00037/0331
| | Arythmol 300 mg Tablets
| PL 00037/0332 |
| |
Go to top of the pageGo to top of the page
More information about this product
Link to this document from your website: http://www.medicines.org.uk/emc/medicine/10622/SPC/